Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial NCT05848258 is currently recruiting/active, with primary completion estimated Feb 2026. No public readout or results available as of Apr 2026; no sources report positive/negative framing of efficacy data.
Found Apr 6, 2026, 2:58 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial is recruiting with estimated primary completion Feb 2026; no results, topline readout, or efficacy interpretation posted on ClinicalTrials.gov or sponsor site. Preclinical/early data mentions are not trial-specific outcomes.
Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:19 PM
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed96% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific Phase 2 efficacy readout was found. The cited sources still describe NCT05848258/ocadusertib as ongoing, with enrollment ongoing or the Phase 2 trial ongoing, so there is no clear positive or negative public outcome to classify yet.
Found Apr 3, 2026, 4:05 PMReviewed Apr 3, 2026, 4:47 PM
NO_DECISIONDismissed96% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific efficacy readout was found. The cited sources indicate NCT05848258 remains ongoing/recruiting, with Lilly pipeline materials showing primary completion around February 2026 and Rigel stating enrollment in the Phase 2a RA trial is ongoing. Without a public results disclosure, the trial cannot be framed as positive or negative.
Found Apr 1, 2026, 6:50 PMReviewed Apr 1, 2026, 7:04 PM